EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis

Ali Alqallaf iD, Drew W Cates, Kandon P Render, Katie A Patel

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231172802 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Ali Alqallaf und 3 weiteren Autor:innen. Beteiligte Einrichtung: SynerGrx, Chamblee, GA, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To review the safety and efficacy of sodium phenylbutyrate and taurursodiol (SP + T) in slowing progression of amyotrophic lateral sclerosis (ALS) compared with pre-existing therapies. Data Sources: A PubMed (from January 1, 2009, to April 13, 2023) and ClinicalTrials.gov search conducted using sodium phenylbutyrate, taurursodiol, AMX0035, riluzole, and edaravone. Additional articles were identified by hand from references. Data Selection and Data Extraction: This included English-language articles evaluating SP + T efficacy or safety in humans for decreasing neuronal death and slowing the progression of ALS. Data Synthesis: In one phase II clinical trial that encompassed an open-label extension phase, disease severity, assessed by the rate of decline in overall score on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised with higher scores indicating more functional ability, was –1.24 points per month with active drug and –1.66 points per month with placebo (difference, 0.42 points per month; 95% CI, 0.03-0.81; P = 0.03). Post hoc analysis found survival benefit of median 4.8 months with active medication compared with placebo. Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs: SP + T is a new US Food and Drug Administration–approved oral suspension for the treatment of ALS. Patients who received active medication through the phase II trial showed decreased rates of disease progression. Overall, SP + T could be considered a potential agent for the treatment of ALS which has a high unmet need.

Conclusion

SP + T is an option for the treatment of ALS; however, additional data regarding efficacy in phase III trials with long-term safety profile considerations, as well as trials to compare current therapy with SP + T, are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisUnited StatesHumansPhenylbutyratesTaurochenodeoxycholic Acid

Stichwörter der Autor:innen

amyotrophic lateral sclerosisnew drug approvalssodium phenylbutyratetaurursodiol

Substanzen

Phenylbutyratessodium phenylbutyrate and taurursodiol4-phenylbutyric acidursodoxicoltaurineTaurochenodeoxycholic Acid

Autor:innen und Institutionen

  • SynerGrx, Chamblee, GA, USA.

ORCID-Profile: Ali Alqallaf

Zitieren

APA

Alqallaf, A., Cates, D. W., Render, K. P., & Patel, K. A. (2024). Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231172802

Vancouver

Alqallaf A, Cates DW, Render KP, Patel KA. Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231172802

BibTeX
@article{Alqallaf2024,
  author = {Alqallaf, Ali and Cates, Drew W and Render, Kandon P and Patel, Katie A},
  title = {Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231172802}
}
Kostenlos starten →